PDF下载 ( 1793 KB)
Research advances in the influence of hepatic stellate cells on precancerous lesions of liver cirrhosis and hepatocellular carcinoma via the TGFβ1-PI3K/AKT signaling pathway
-
摘要:
肝硬化-肝细胞癌癌前病变的恶性转变导致肝癌的形成。肝星状细胞（HSC）通过TGFβ1-PI3K/AKT信号通路影响肝细胞癌癌前病变细胞产生、肝纤维化微环境的形成以及两者相互作用。了解肝硬化-肝细胞癌癌前病变的恶变机制与HSC和TGFβ1-PI3K/AKT信号通路的关系,将有助于深入了解肝细胞癌的发生机制。通过调控HSC或干预TGFβ1-PI3K/AKT信号通路可阻止甚至或逆转肝硬化向肝细胞癌的进展,为预防和干预肝细胞癌发生提供新的思路和治疗靶点。
Abstract:The malignant transformation of the precancerous lesions of liver cirrhosis and hepatocellular carcinoma ( HCC) leads to the formation of liver cancer. Hepatic stellate cells ( HSCs) play a role in the production of cells in precancerous lesions of HCC, the formation of hepatic fibrosis microenvironment, and the interaction between them via the TGFβ1-PI3 K/AKT signaling pathway. An understanding of the mechanism for the malignant transformation of the precancerous lesions of liver cirrhosis and HCC and the association between HSCs and the TGFβ1-PI3 K/AKT signaling pathway helps to investigate the pathogenesis of HCC. Regulation of HSCs or intervention of the TGFβ1-PI3 K/AKT signaling pathway can inhibit or reverse the progression of liver cirrhosis to HCC, which provides new thoughts and therapeutic targets for prevention and intervention of the development of HCC.
-
[1]VENOOK AP, PAPANDREOU C, FURUSE J, et al.The incidence and epidemiology of hepatocellular carcinoma:a global and regional perspective[J].Oncologist, 2010, 15 Suppl 4:5-13. [2]GATENBY RA.A change of strategy in the war on cancer[J].Nature, 2009, 459 (7246) :508-509. [3]LI Y, ZHANG Z, SHI J, et al.Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBVassociated liver cirrhosis in China[J].Int J Clin Exp Med, 2015, 8 (1) :1205-1212. [4]KEW MC.The role of cirrhosis in the etiology of hepatocellular carcinoma[J].J Gastrointest Cancer, 2014, 45 (1) :12-21. [5]JIAO JZ, LI JT, YAN SG, et al.Current research status of precancerous dysplastic nodules in hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (5) :974-978. (in Chinese) 焦俊喆, 李京涛, 闫曙光, 等.肝细胞癌癌前异型增生结节的研究现状[J].临床肝胆病杂志, 2017, 33 (5) :974-978. [6]ZHANG L, ZHOU F, TEN DIJKE P.Signaling interplay between transforming growth factor-βreceptor and PI3K/AKT pathways in cancer[J].Trends Biochem Sci, 2013, 38 (12) :612-620. [7]ZHOU Q, LUI VW, YEO W.Targeting the PI3K/Akt/m TOR pathway in hepatocellular carcinoma[J].Future Oncol, 2011, 7 (10) :1149-1167. [8]MORMONE E, GEORGE J, NIETO N.Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches[J].Chem Biol Interact, 2011, 193 (3) :225-231. [9]WHITTAKER S, MARAIS R, ZHU AX.The role of signaling pathways in the development and treatment of hepatocellular carcinoma[J].Oncogene, 2010, 29 (36) :4989-5005. [10]COULOUARN C, CORLU A, GLAISE D, et al.Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma[J].Cancer Res, 2012, 72 (10) :2533-2542. [11]SANTAMATO A, FRANSVEA E, DITURI F, et al.Hepatic stellate cells stimulate HCC cell migration via laminin-5 production[J].Clin Sci (Lond) , 2011, 121 (4) :159-168. [12]HERNANDEZ-GEA V, TOFFANIN S, FRIEDMAN SL, et al.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma[J].Gastroenterology, 2013, 144 (3) :512-527. [13]THOMPSON AI, CONROY KP, HENDERSON NC.Hepatic stellate cells:central modulators of hepatic carcinogenesis[J].BMC Gastroenterol, 2015, 15:63. [14]SONG Y, KIM SH, KIM KM, et al.Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids[J].Sci Rep, 2016, 6:36750. [15]WANG X, HASSAN W, JABEEN Q, et al.Interdependent and independent multidimensional role of tumor microenvironment on hepatocellular carcinoma[J].Cytokine, 2017.[Epub ahead of print] [16]TAHMASEBI BIRGANI M, CARLONI V.Tumor microenvironment, a paradigm in hepatocellular carcinoma progression and therapy[J].Int J Mol Sci, 2017, 18 (2) :405. [17]XIA YH, LU Z, ZHAO M, et al.Tumor-specific hepatic stellate cells (t HSCs) induces DIgR2 expression in dendritic cells to inhibit T cells[J].Oncotarget, 2017, 8 (33) :55084-55093. [18]WU K, DING J, CHEN C, et al.Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development[J].Hepatology, 2012, 56 (6) :2255-2267. [19]KATZ LH, LI Y, CHEN JS, et al.Targeting TGF-βsignaling in cancer[J].Expert Opin Ther Targets, 2013, 17 (7) :743-760. [20]GUPTA DK, SINGH N, SAHU DK.TGF-βmediated crosstalk between malignant hepatocyte and tumor microenvironment in hepatocellular carcinoma[J].Cancer Growth Metastasis, 2014, 7:1-8. [21]YOSHIDA K, MURATA M, YAMAGUCHI T, et al.Reversible human TGF-βsignal shifting between tumor suppression and fibro-carcinogenesis:implications of smad phospho-isoforms for hepatic epithelial-mesenchymal transitions[J].J Clin Med, 2016, 5 (1) .pii:E7. [22]ZHU HB, YANG YS, GUO MZ.Transforming growth factorβ (TGF-β) and hepatocellular carcinoma[J].Chin J Gastroenterol Hepatol, 2012, 21 (3) :206-209. (in Chinese) 朱宏斌, 杨云生, 郭明洲.肝癌中转化生长因子 (TGF) -β信号转导通路的研究进展[J].胃肠病学和肝病学杂志, 2012, 21 (3) :206-209. [23]COULOUARN C, CLEMENT B.Stellate cells and the development of liver cancer:therapeutic potential of targeting the stroma[J].J Hepatol, 2014, 60 (6) :1306-1309. [24]YOSHIDA K, MURATA M, YAMAGUCHI T, et al.TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review) [J].Int J Oncol, 2014, 45 (4) :1363-1371. [25]ARRESE M, CABRERA D, HERNANDEZ A, et al.TGF-βand hepatocellular carcinoma:when a friend becomes an enemy[J].Curr Protein Pept Sci, 2017.[Epub ahead of print] [26]ZHANG YE.Non-Smad pathways in TGF-beta signaling[J].Cell Res, 2009, 19 (1) :128-139. [27]SPANGLE JM, ROBERTS TM, ZHAO JJ.The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer[J].Biochim Biophys Acta, 2017, 1868 (1) :123-131. [28]JOSHI S, SINGH AR, DURDEN DL.Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma[J].Cancer Chemother Pharmacol, 2015, 75 (3) :595-608. [29]SINGH AR, JOSHI S, BURGOYNE AM, et al.Single agent and synergistic activity of the"first-in-class"dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma[J].Mol Cancer Ther, 2016, 15 (11) :2553-2562. [30]GULHATI P, BOWEN KA, LIU J, et al.m TORC1 and m TORC2 regulate EMT, motility, and metastasis of colorectal cancer via Rho A and Rac1 signaling pathways[J].Cancer Res, 2011, 71 (9) :3246-3256. 期刊类型引用(11)
1. 鞠迪，李汨，韩曼，房冰莹，闫曙光，李京涛. 益脾养肝方对大鼠肝癌前病变肝干细胞恶性转化的影响和作用机制. 临床肝胆病杂志. 2022(04): 865-871 . 
本站查看2. 陈艳，王桂洁，余青. 当归注射液对肝硬化大鼠门静脉压力及TGFβ1/PI3K通路的调节作用. 中西医结合肝病杂志. 2022(07): 617-621 . 
百度学术3. 刘蕊洁，曹旭，杨先照，梁亦骏，叶永安. 益肝消癥方联合恩替卡韦对乙型肝炎病毒诱导肝星状细胞增殖、凋亡的调节作用. 中华中医药杂志. 2022(11): 6796-6800 . 百度学术4. 刘蕊洁，杨先照，张嘉鑫，叶永安. 益肝消癥方对大鼠肝癌前病变肝细胞凋亡因子Bcl-2、Bax mRNA及蛋白质表达的影响. 中西医结合肝病杂志. 2021(01): 56-59 . 百度学术5. 杨洁，贺武斌，安妮，孔雯聪，苏荣健，王学哲. 葡萄糖调节蛋白78对肝癌细胞放射敏感性的调控作用及其机制. 吉林大学学报(医学版). 2021(04): 888-895 . 百度学术6. 宁麟，孙建光. 原发性肝癌癌前病变中西医研究进展. 世界科学技术-中医药现代化. 2021(10): 3590-3598 . 百度学术7. 黄倩，李京涛，张海博，魏海梁，闫曙光，常占杰. 李京涛诊治肝癌癌前病变经验探析. 中西医结合肝病杂志. 2020(03): 246-248 . 百度学术8. 邓琰，吴凡，陈芦斌，李宁宇，寇伟伟. 内镜下食管静脉曲张套扎术治疗乙肝肝硬化后25-(OH)D_3水平与出血风险的关系. 现代消化及介入诊疗. 2020(06): 761-764 . 百度学术9. 吴杰，李京涛，魏海梁，闫曙光，范妤，郭英君，常占杰. microRNA调控肝星状细胞活化干预肝癌癌前病变的研究进展. 临床肝胆病杂志. 2020(07): 1650-1654 . 本站查看10. 张丽泳，欧阳晓晖，苏秀兰. 线粒体自噬的分子机制及其对肝脏疾病潜在治疗价值的研究进展. 现代免疫学. 2019(01): 68-71 . 百度学术11. 张红宇，李娟，余祖江，江河清，梁红霞，武淑环. 调控miR-495、P4HA2的表达对肝纤维化和肝细胞癌发生机制研究. 中西医结合肝病杂志. 2019(04): 313-316 . 百度学术其他类型引用(7)
-
百度学术
下载:
